0001209191-22-023860.txt : 20220408
0001209191-22-023860.hdr.sgml : 20220408
20220408162101
ACCESSION NUMBER: 0001209191-22-023860
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220406
FILED AS OF DATE: 20220408
DATE AS OF CHANGE: 20220408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rovaldi Christopher
CENTRAL INDEX KEY: 0001706040
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 22817261
MAIL ADDRESS:
STREET 1: C/O ACCELERON PHARMA INC.
STREET 2: 128 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-06
0
0001664710
Keros Therapeutics, Inc.
KROS
0001706040
Rovaldi Christopher
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
0
1
0
0
Chief Operating Officer
Common Stock
2022-04-06
4
M
0
1728
16.00
A
1728
D
Common Stock
2022-04-06
4
S
0
1728
65.00
D
0
D
Employee Stock Option (right to buy)
16.00
2022-04-06
4
M
0
1728
0.00
D
2030-04-07
Common Stock
1728
8002
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Esther Cho, Attorney-in-Fact
2022-04-08